Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sevoflurane + propofol (Ruijin Hospital)
- Development stage
- Phase 4
- Lead developer
- Ruijin Hospital
- Modality
- Small Molecules
- Administration
- Inhalation, Intravenous
01
Overview
Sevoflurane + propofol refers to a combined anesthetic maintenance regimen evaluated by Ruijin Hospital for use in patients with coronary artery disease undergoing off-pump coronary artery bypass graft (OPCAB) surgery. This combination therapy utilizes sevoflurane, a volatile halogenated ether inhaled anesthetic, and propofol, a short-acting intravenous hypnotic agent. The primary objective of this specific clinical application was to evaluate the protective effects of the combination on circulating lymphocytes against surgery-induced apoptosis. Mechanistically, both agents modulate the GABA-A receptor, while sevoflurane also acts as an NMDA receptor antagonist. Clinical study results indicated that the combination regimen was superior to sevoflurane alone in protecting circulating lymphocytes from apoptosis, a process associated with the reduced expression of caspase-3 and apoptosis-inducing factor (AIF).
- Other names
- combine of sevoflurane and propofolsevoflurane-propofol combination
02
Targets
GABRR (GABA-A receptor subunit rho)NaV (Voltage-gated sodium channels)GABRA2 (Gamma-aminobutyric acid receptor subunit alpha 2)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on sevoflurane + propofol (Ruijin Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sevoflurane + propofol (Ruijin Hospital).